Introduction {#sec1_1}
============

Chronic necrotizing and granulomatous meningoencephalitis are idiopathic inflammatory diseases that commonly affect the central nervous system of canines, however, have not been identified in humans yet. These diseases have been associated with specific dog breeds, causing a progressive fatal disease with consistent neuropathological changes \[[@B1]\]. Canine meningoencephalitis is further classified into necrotizing and granulomatous meningoencephalitis based on pathological findings, yet these subclasses are suspected to share a possibly autoimmune pathogenesis \[[@B2]\]. Although these idiopathic inflammatory central nervous system diseases have been identified and investigated within the canine species, necrotizing granulomatous meningoencephalitis has not been readily identified and studied in humans. Here, we report a case of chronic necrotizing granulomatous meningoencephalitis in an adult female patient.

Case Report {#sec1_2}
===========

The patient is a 55-year-old right-handed female with a past medical history of previous diagnosis of chronic lymphocytic leukemia, and recurrent TB exposure presenting with new-onset daily frontal headaches. She originally presented to her primary care physician with intermittent burning left frontal headaches that were worse with exertion and without associated focal neurologic deficit. Initial neurological examination was unremarkable. MRI of the brain revealed an 11-mm left frontal lobe enhancing lesion with surrounding vasogenic edema, as well as multiple punctate bilateral cortical/subcortical enhancing lesions (Fig. [1](#F1){ref-type="fig"}). Her headaches began to worsen in intensity and frequency and were associated with new-onset right facial tingling and intermittent bilateral upper and lower extremity pain. Extensive infectious, autoimmune, and neoplastic workup was completed and was unremarkable. Malignancy workup included CT of the chest, abdomen, and pelvis, followed by a whole-body bone scan, PET-CT, and flow cytometry which were all negative for malignancy. A summary of the infectious and autoimmune workup can be found in Table [1](#T1){ref-type="table"}.

The patient was referred to neurosurgery for open brain biopsy targeting the left frontal enhancing lesion. Postoperative neurologic examination demonstrated a mild expressive aphasia with word finding difficulties. Neuropathology revealed chronic granulomatous inflammation of the brain and meninges. The granulomas noted within the meninges showed central necrosis surrounded by a rim of lymphocytes, plasma cells, and epithelioid histiocytes in addition to eosinophils and giant cells. Marked fibrosis and burnt-out granulomas were seen within both the meninges and brain tissue with dense perivascular lymphoplasmacytic infiltrate along with reactive gliosis within the cerebral cortex. These findings were consistent with chronic necrotizing granulomatous meningoencephalitis. There were no findings on biopsy consistent with mycobacterial infection.

The patient was treated with intravenous 1,000 mg Solumedrol for 3 days followed by a 6-week prednisone taper. Over the next 6 months, the patient remained clinically stable with mild expressive aphasia. Six months after treatment, she began having staring spells that started with a strange feeling. No EEG correlate was noted on long-term EEG monitoring; however, she was started on Lamictal for high suspicion of focal seizures, with complete resolution of symptoms. She remained clinically and radiographically stable without additional treatment for 4 years until the most recent MRI in 2018 suggesting recurrence (Fig. [2](#F2){ref-type="fig"}).

Discussion {#sec1_3}
==========

Chronic necrotizing granulomatous meningoencephalitis, although extensively studied in canines, has yet to be described in humans. Canines can display a wide variety of clinical symptoms depending on the location of the lesions. Common symptoms of necrotizing meningoencephalitis in canines include seizures, paresis, ataxia, visual defects, lethargy, behavioral changes, excessive walking in circles, and death \[[@B3], [@B4]\]. Although necrotizing meningoencephalitis and granulomatous meningoencephalitis can be classified as two distinct processes, the proportion of inflammatory cells does not differ among them, suggesting that they are a spectrum of the same disease with shared pathogenesis \[[@B5]\]. Pathology of these diseases consist of necrosis with infiltration of lymphocytes, plasma cells, and histiocytes within the leptomeninges and the cerebral cortex \[[@B5]\]. Granulomatous lesions with epithelioid cells are seen in addition to perivascular cuffs consisting of lymphocytes, plasma cells, and macrophages \[[@B5]\].

Although the pathogenesis remains unclear, research suggests a possible autoimmune mediated delayed-type hypersensitivity response due to the significant presence of CD3 T-lymphocytes and major histocompatibility complex class II \[[@B5], [@B6]\]. It is theorized that the granulomatous nature of the disease further supports an immune mediated etiology. Variants of meningoencephalitis can be associated with specific canine breeds with a higher predilection for females, although both sexes are affected \[[@B7]\].

Studies have yet to identify a single infectious, environmental, or genetics basis, suggesting that multiple factors play a role in disease pathogenesis \[[@B6]\]. Genetic predisposition has been identified in certain breeds \[[@B1]\]. Common infectious causes of canine central nervous system disease, such as canine distemper, *Cryptococcus neoformans, Ehrlichia canis, Neospora caninum, Rickettsia rickettsii*, and *Toxoplasma gondii*, have yet to be isolated in canines with necrotizing granulomatous meningoencephalitis \[[@B4]\]. *Mycoplasma canis* has been isolated at a higher frequency from canines with necrotizing granulomatous meningoencephalitis; however, this difference was not found to be statistically significant when compared to controls \[[@B1]\]. There has yet to be correlation with any viral infections as well, but it remains unclear if possible past exposure could potentiate these diseases \[[@B3]\].

Overall, definitive diagnosis is made postmortem during autopsy of deceased or euthanized canines. It remains difficult to diagnose canines prior to autopsy but living diagnosis can be supported by CSF findings that exclude other infectious etiologies. Additionally, MRI or CT findings consisting of solitary or multiple contrast-enhancing lesions can back up the diagnosis when suspicious for inflammatory meningoencephalitis \[[@B7]\].

There is currently no gold standard treatment for necrotizing granulomatous meningoencephalitis in canines as treatment protocols are largely based on case reports alone and overall it represents a broad spectrum of diseases \[[@B6]\]. The typical treatment for these canines includes immunosuppression with corticosteroids, although neurological symptoms can recur after treatment \[[@B7]\]. Other secondary immunomodulatory drugs such as cyclosporine, cytosine arabinoside, leflunomide, lomustine, and mycophenolate mofetil show promising results but require further evaluation for efficacy \[[@B6]\]. Additionally, use of antiepileptics are suggested in canines with seizures \[[@B2]\]. Despite treatment, the prognosis remains poor, yet canines with focal disease tend to survive longer than those with disseminated disease \[[@B6]\].

After a thorough literature review, this is the first case of human chronic necrotizing granulomatous meningoencephalitis to be reported. The similar pathological findings in canines with necrotizing and granulomatous meningoencephalitis suggests that this predominantly canine disease can afflict humans as well. Further research is necessary to determine pathogenesis in both humans and canines. This case demonstrates that the use of glucocorticoids for the treatment of necrotizing granulomatous meningoencephalitis, as in canines, may slow progression of the disease. Our patient remained clinically stable with no evidence of radiologic progression for 4 years after initial steroid treatment. Further research is necessary to determine ideal treatment protocols and to further evaluate the use of immunomodulatory therapy in this disease entity.
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![MRI of the brain with and without gadolinium at presentation. **a--c** T1 post contrast images demonstrating nodular enhancement in the left frontal cortex (**a**), left parietal cortex (**b**), and right occipital cortex (**c**). **d** T2 imaging with vasogenic edema in the left frontal cortex with central hypointensity in the area of enhancement. **e**, **f** T2 FLAIR with bilateral hyperintensities largely surrounding the area of enhancement.](crn-0010-0302-g01){#F1}

![MRI of the brain with and without gadolinium (4 years later). **a--c** T1 post contrast images demonstrating new nodular enhancement in the left frontal cortex adjacent to biopsy site (**a**), two small lesions in the left parietal cortex (**b**), and new left anterior temporal cortex (**c**). **d** T2 imaging with vasogenic edema in the left frontal cortex with central hypointensity in the area of biopsy. **e**, **f** T2 FLAIR wit bilateral hyperintensities in the areas of enhancement.](crn-0010-0302-g02){#F2}

###### 

Summary of laboratory and imaging results

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Serum studies                                                        CSF studies                                                                            Imaging/other                                                    
  ----------------------------------- -------------------------------- -------------------------------------- ----------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------
  CBC                                 WBC - 16.27 k/µL\                Cell count                             RBC - 15\                                       CT of the chest, abdomen and pelvis                              mild bullous emphysema, no primary malignancy or metastases
                                      Hgb - 14.3 g/dL\                                                        lymphocyte - 1                                                                                                   
                                      Plt - 411 k/µL                                                                                                                                                                           

                                                                                                                                                                                                                               

  HgbA~1c~                            7.8%                             Glucose                                65 mg/dL                                        PET-CT                                                           mild increased asymmetric uptake in right tonsil

                                                                                                                                                                                                                               

  ANA                                 negative                         Protein                                44 mg/dL                                        Nuclear medicine no evidence of skel-bone scan etal metastases   

                                                                                                                                                                                                                               

  Complement                          C3 - 161 mg/dL (ref. 90--180)\   Cytology                               benign                                          Mammogram                                                        normal
                                      C4 - 36 mg/dL (ref. 10--140)                                                                                                                                                             

                                                                                                                                                                                                                               

  SSA-SSB                             negative                         Myelin basic protein                   \<2 mg/L (ref. 0--4)                            Colonoscopy                                                      tubular adenoma

                                                                                                                                                                                                                               

  ANCA                                negative                         IgG Index                              0.42 (ref. \<0.66)                              PPD                                                              negative

                                                                                                                                                                                                                               

  ESR                                 17 mm/h (ref. 0--20)             Oligoclonal bands                      5 gamma-restricted bands with serum correlate   EEG ×4                                                           left frontotemporal slowing without epileptiform discharges

                                                                                                                                                                                                                               

  CRP                                 7.58 ml/L (ref. 0--5)            Culture anaerobic/aer-no growth obic                                                                                                                    

                                                                                                                                                                                                                               

  ACE                                 6 U/L (ref. 9--67)               Gram stain                             no organisms or PMNs                                                                                             

                                                                                                                                                                                                                               

  FTA-ABS                             nonreactive                      Fungal smear                           no yeast or hyphae                                                                                               

                                                                                                                                                                                                                               

  Quantiferon                         negative                         Fungal culture                         no growth                                                                                                        

                                                                                                                                                                                                                               

  Histoplasmosis/ blastomycosis IgG   negative                         Cryptococcal antigen                   negative                                                                                                         

                                                                                                                                                                                                                               

  HIV negative                        negative                                                                                                                                                                                 

                                                                                                                                                                                                                               

  Hepatitis panel                     negative                                                                                                                                                                                 

                                                                                                                                                                                                                               

  SPEP                                normal                                                                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
